Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.
Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.
The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.
EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.
The EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.
EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.